- Home
- RMTI vs BOLD Comparison
RMTI vs BOLD Comparison
Compare RMTI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- BOLD
- Stock Information
- Founded
- RMTI 1994
- BOLD 2018
- Country
- RMTI United States
- BOLD United States
- Employees
- RMTI N/A
- BOLD N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- BOLD
- Sector
- RMTI Health Care
- BOLD
- Exchange
- RMTI Nasdaq
- BOLD Nasdaq
- Market Cap
- RMTI 34.9M
- BOLD 30.3M
- IPO Year
- RMTI 1998
- BOLD 2024
- Fundamental
- Price
- RMTI $1.17
- BOLD $1.50
- Analyst Decision
- RMTI Strong Buy
- BOLD Hold
- Analyst Count
- RMTI 2
- BOLD 1
- Target Price
- RMTI $4.00
- BOLD N/A
- AVG Volume (30 Days)
- RMTI 194.8K
- BOLD 63.1K
- Earning Date
- RMTI 05-12-2025
- BOLD 05-16-2025
- Dividend Yield
- RMTI N/A
- BOLD N/A
- EPS Growth
- RMTI N/A
- BOLD N/A
- EPS
- RMTI N/A
- BOLD N/A
- Revenue
- RMTI $101,489,000.00
- BOLD N/A
- Revenue This Year
- RMTI N/A
- BOLD N/A
- Revenue Next Year
- RMTI $10.42
- BOLD N/A
- P/E Ratio
- RMTI N/A
- BOLD N/A
- Revenue Growth
- RMTI 21.38
- BOLD N/A
- 52 Week Low
- RMTI $0.86
- BOLD $1.06
- 52 Week High
- RMTI $5.15
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- RMTI 50.40
- BOLD N/A
- Support Level
- RMTI $1.08
- BOLD N/A
- Resistance Level
- RMTI $1.31
- BOLD N/A
- Average True Range (ATR)
- RMTI 0.08
- BOLD 0.00
- MACD
- RMTI 0.02
- BOLD 0.00
- Stochastic Oscillator
- RMTI 53.33
- BOLD 0.00
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.